Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Effectiveness of Advanced Practice Nurse-Led Telehealth on Readmissions

Conditions:   Acute Myocardial Infarction;   Acute Coronary Syndrome
Intervention:   Other: APN-led Telemedicine
Sponsors:   National University Heart Centre, Singapore;   National University Hospital, Singapore
Not yet recruiting - verified June 2015

Clinical Risk Score Predicting the Cardiac Rupture in Patients With ST-elevation Myocardial Infarction

Condition:   Cardiac Rupture
Intervention:   Other: Grouping by different risk stratification
Sponsor:   Chinese PLA General Hospital
Completed - verified May 2015

The Effects of Journaling on Health-Related Mood and Clinical Outcomes in Post-MI Patients

Conditions:   Myocardial Infarction;   Psychosocial Factors
Interventions:   Behavioral: Gratitude Journaling Plus SOC;   Behavioral: Memorable Events Journaling Plus SOC
Sponsors:   University of California, San Diego;   San Diego Veterans Healthcare System
Enrolling by invitation - verified May 2015

Early Sleeve Gastrectomy In New Onset Diabetic Obese Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Procedure: Laparoscopic Sleeve Gastrectomy plus conventional medical therapy;   Drug: Conventional medical therapy
Sponsors:   Azienda Ospedaliera Santa Maria, Terni, Italy;   Ethicon Endo-Surgery
Not yet recruiting - verified June 2015

The Risk of Major Bleeding With Novel Anti-platelets: A Comparison of Ticagrelor With Clopidogrel in a Real World Population of 5000 Patients Treated for Acute Coronary Syndrome

Conditions:   Acute Coronary Syndrome;   Bleeding;   Novel Anti-platelets;   Ticagrelor;   Clopidogrel
Intervention:   Drug: Ticagrelor
Sponsors:   Aintree University Hospitals NHS Foundation Trust;   Liverpool Heart and Chest Hospital NHS Foundation Trust;   Royal Liverpool and Broadgreen University Hospitals NHS Trust;   Countess of Chester NHS Foundation Trust;   St Helens & Knowsley Teaching Hospitals NHS Trust
Recruiting - verified June 2015

Family-based Approach to Promotion of Health Project 2

Conditions:   Lifestyle Intervention;   Atherosclerosis;   Cardiovascular Risk Factor
Interventions:   Behavioral: Intensive Individual Intervention Program;   Behavioral: Peer-To-Peer Program Intervention
Sponsors:   Icahn School of Medicine at Mount Sinai;   American Heart Association
Not yet recruiting - verified June 2015

Nephrologist Follow-up Versus Usual Care After Acute Kidney Injury

Conditions:   Acute Kidney Injury;   Chronic Kidney Disease
Intervention:   Behavioral: AKI Follow-up Clinic
Sponsors:   St. Michael's Hospital, Toronto;   Sunnybrook Health Sciences Centre;   University Health Network, Toronto;   Mount Sinai Hospital, Canada
Not yet recruiting - verified June 2015

Understanding Liver Fat Metabolism: Studies to Understand the Role of Dietary Sugars on Liver Fat Metabolism

Condition:   Hypertriglyceridaemia
Intervention:   Other: Sugar study
Sponsor:   University of Oxford
Recruiting - verified June 2015

Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany and the UK: REACT-AF2

Condition:   Non-valvular Atrial Fibrillation
Intervention:  
Sponsors:   Bristol-Myers Squibb;   IMS Health;   Oxon Epidemiology
Active, not recruiting - verified June 2015

Saxagliptin and Cardiac Structure and Function

Conditions:   Diabetes Mellitus, Non-Insulin-Dependent;   Heart Failure
Interventions:   Drug: Saxagliptin;   Drug: Saxagliptin;   Drug: saxagliptin
Sponsor:   St. Michael's Hospital, Toronto
Recruiting - verified June 2015

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Not yet recruiting - verified June 2015

A Trial of Autologous Bone Marrow Derived Stem Cells in Paediatric Heart Failure

Condition:   Dilated Cardiomyopathy
Intervention:   Biological: stem cell injection
Sponsor:   Great Ormond Street Hospital for Children NHS Foundation Trust
Completed - verified June 2015

A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction

Condition:   Heart Failure
Interventions:   Drug: BAY1142524;   Drug: BAY1142524;   Drug: BAY1142524;   Drug: BAY1142524;   Drug: Placebo
Sponsor:   Bayer
Not yet recruiting - verified June 2015

Real-Life Evidence on Stroke Prevention in SPAF

Condition:   Atrial Fibrillation (Prevention of Stroke)
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Vitamin K antagonists
Sponsors:   Bayer;   Janssen, LP
Recruiting - verified June 2015

Cognitive Behavioural Therapy for Menopausal Symptoms

Condition:   Menopausal Depression
Intervention:   Other: Cognitive Behavioural Therapy for Menopausal Symptoms
Sponsors:   St. Joseph's Healthcare Hamilton;   Ontario Mental Health Foundation
Not yet recruiting - verified June 2015

A Prospective, Single-Blinded, Multi-Center, Randomized, Controlled, Registered Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent® System) in the Treatment of Patients With Coronary Heart Disease

Condition:   Coronary Heart Disease
Interventions:   Device: MiStentTM;   Device: TIVOLI
Sponsors:   Micell Technologies;   Hefei Life Science Medical Instruments Co. Ltd.;   Giant Med-Pharma Services Inc.;   CCRF Consulting Co., Ltd.
Not yet recruiting - verified June 2015

Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure

Condition:   Coronary Artery Disease.
Interventions:   Drug: Ivabradine;   Drug: Placebo
Sponsor:   Servier
Completed - verified June 2015

A Study of CSL112 in Healthy Adults and in Adults With Moderate Renal Impairment

Condition:   Acute Myocardial Infarction
Interventions:   Biological: CSL112;   Other: Placebo
Sponsor:   CSL Behring
Recruiting - verified June 2015

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Condition:   Cost Sharing, Acute Coronary Syndrome,
Intervention:   Other: Study voucher card
Sponsors:   AstraZeneca;   Duke Clinical Research Institute
Recruiting - verified June 2015

High Fidelity Simulation vs Standard Teaching Training of Cardiac Resuscitation

Condition:   Cardiac Arrest
Interventions:   Device: Laerdal®;   Behavioral: huma patient based training;   Behavioral: traditionally teaching
Sponsor:   University of Monastir
Recruiting - verified June 2015

Study Comparing the MiStent SES Versus the XIENCE EES Stent

Condition:   Coronary Stenosis
Interventions:   Device: MiStent;   Device: XIENCE EES
Sponsors:   ECRI bv;   Micell Technologies;   Stentys
Recruiting - verified June 2015

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Conditions:   HIV Infections;   Cardiovascular Diseases
Interventions:   Drug: Pitavastatin;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Heart, Lung, and Blood Institute (NHLBI);   Kowa Pharmaceuticals America, Inc.
Recruiting - verified June 2015

Fractional Flow Reserve Versus Angiography Randomization for Graft Optimization Trial

Conditions:   Coronary Artery Disease;   Coronary Disease;   Myocardial Ischemia;   Arteriosclerosis;   Cardiovascular Diseases
Interventions:   Procedure: Fractional flow reserve-guided CABG;   Procedure: Angiography-guided CABG
Sponsor:   Odense University Hospital
Recruiting - verified June 2015

Patient and Provider Assessment of Lipid Management Registry

Conditions:   Hyperlipidemia;   Hypercholesterolemia;   Cardiovascular Disease;   Diabetes;   Chronic Kidney Disease (CKD);   Hypertension;   Smoking;   Myocardial Infarction (MI);   Unstable Angina;   Angina;   Coronary Artery Disease (CAD);   Stroke;   Transient Ischemic Attack (TIA);   Carotid Stenosis;   Peripheral Arterial Disease;   Atherosclerosis;   Claudication
Intervention:  
Sponsors:   Duke University;   Regeneron Pharmaceuticals;   Sanofi
Recruiting - verified June 2015

Perioperative Endothelial Dysfunction

Condition:   Myocardial Injury
Intervention:   Procedure: Elective colon cancer surgery
Sponsor:   University Hospital Koge
Completed - verified June 2015

BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Intervention:   Device: BioMonitor
Sponsor:   Biotronik SE & Co. KG
Recruiting - verified June 2015

A Study of VentriGel in Early and Late Post-myocardial Infarction Patients

Conditions:   Myocardial Infarction;   Heart Failure;   Left Ventricular Remodeling
Intervention:   Biological: VentriGel
Sponsor:   Ventrix, Inc.
Not yet recruiting - verified June 2015

RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified June 2015

A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction

Conditions:   Heart Attack;   NSTEMI
Interventions:   Biological: AMI MultiStem cells;   Other: Sham
Sponsors:   Athersys, Inc;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2015

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified June 2015

Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Acute Myocardial Infarction

Conditions:   ST-segment Elevation Myocardial Infarction;   Non-ST-segment Elevation Myocardial Infarction;   VA Drug Interactions [VA Drug Interaction]
Interventions:   Drug: Morphine;   Drug: Placebo;   Drug: Ticagrelor
Sponsor:   Collegium Medicum w Bydgoszczy
Recruiting - verified June 2015

Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR

Condition:   Peripheral Artery Disease (PAD)
Interventions:   Drug: Ticagrelor;   Drug: Comparator
Sponsors:   AstraZeneca;   CPC Clinical Research
Recruiting - verified June 2015

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2015

Ethnicity and Onset of Cardiovascular Disease: A CALIBER Study

Conditions:   Abdominal Aortic Aneurysm;   Coronary Heart Disease;   Sudden Cardiac Death;   Intracerebral Haemorrhage;   Heart Failure;   Ischemic Stroke;   Myocardial Infarction;   Stroke;   Peripheral Arterial Disease;   Stable Angina Pectoris;   Subarachnoid Haemorrhage;   Transient Ischemic Attack;   Unstable Angina;   Cardiac Arrest
Intervention:  
Sponsors:   University College, London;   Wellcome Trust;   National Institute for Health Research, United Kingdom;   London School of Hygiene and Tropical Medicine
Active, not recruiting - verified July 2015

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

Condition:   Acute Myocardial Infarction
Interventions:   Biological: CSL112;   Biological: Placebo
Sponsor:   CSL Behring
Recruiting - verified June 2015

Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events

Condition:   Pulmonary Disease, Chronic Obstructive
Intervention:  
Sponsor:   Boehringer Ingelheim
Active, not recruiting - verified July 2015

Sequential Expansion of Comparative Effectiveness of Anticoagulants

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2015

Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study

Condition:   HIV Infection
Interventions:   Drug: Aspirin 81 mg daily;   Drug: Atorvastatin 40 mg daily
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2014

Utilising Lifemap to Investigate Malignant Arrhythmia Therapy

Conditions:   Ischemic Cardiomyopathy;   Sudden Cardiac Death;   Implantable Defibrillator User;   Myocardial Infarction;   Arrhythmias, Cardiac
Intervention:  
Sponsors:   University Hospitals, Leicester;   University of Leicester
Recruiting - verified June 2015

Improving the Quality of Private Sector Health Care in West Bengal

Conditions:   Myocardial Infarction;   Diarrhea (Dysentery);   Asthma
Interventions:   Other: Training;   Other: Control
Sponsors:   Abdul Latif Jameel Poverty Action Lab;   National Rural Health Mission, Government of West Bengal, India;   Liver Foundation, West Bengal;   World Bank
Completed - verified June 2015

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Condition:   Atrial Fibrillation
Interventions:   Drug: Apixaban;   Drug: Parenteral heparin and/or oral Vitamin K antagonist
Sponsors:   Pfizer;   Bristol-Myers Squibb
Recruiting - verified June 2015

Intracoronary Infusion of Mononuclear Cells Autologous Bone Marrow in Patients With Chronic Coronary Occlusion and Ventricular Dysfunction, Previously Revascularized.

Condition:   Coronary Atherosclerosis and Other Heart Disease
Interventions:   Other: Mononuclear cells from autologous bone marrow;   Drug: Conventional medical treatment
Sponsors:   Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud;   Iniciativa Andaluza en Terapias Avanzadas 
Recruiting - verified June 2015

Prehospital Tranexamic Acid Use for Traumatic Brain Injury

Condition:   Traumatic Brain Injury
Interventions:   Drug: 1 gram Tranexamic Acid (TXA);   Drug: 2 grams TXA;   Drug: 0.9% Sodium Chloride injectable
Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI);   U.S. Army Medical Research and Materiel Command;   Canadian Institutes of Health Research  (CIHR);   Heart and Stroke Foundation of Canada;   American Heart Association;   Defence Research and Development Canada
Recruiting - verified June 2015

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified July 2015

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified July 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Acenocoumarol
Sponsor:   Bayer
Recruiting - verified June 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Phenprocoumon
Sponsor:   Bayer
Recruiting - verified June 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsor:   Bayer
Recruiting - verified June 2015

GLORIA-AF Registry Program (Phase II/III)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2015

A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)

Condition:   Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Withdrawn - verified July 2015

ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial

Condition:   End Stage Renal Failure on Dialysis
Interventions:   Drug: Spironolactone;   Drug: Placebo
Sponsors:   University Hospital, Brest;   Central Hospital, Nancy, France;   Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified June 2015

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: rivaroxaban 2.5 mg;   Drug: rivaroxaban 15 mg;   Drug: rivaroxaban 10 mg;   Drug: aspirin (ASA);   Drug: vitamin K antagonist (VKA);   Drug: clopidogrel;   Drug: prasugrel;   Drug: ticagrelor
Sponsors:   Janssen Scientific Affairs, LLC;   Bayer
Recruiting - verified June 2015

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

Conditions:   Pancreatic Cancer;   Pancreatic Carcinoma Non-resectable;   Locally Advanced Malignant Neoplasm
Interventions:   Drug: FOLFIRINOX;   Biological: Algenpantucel-L Immunotherapy;   Radiation: 5-FU Chemoradiation;   Drug: Gemcitabine;   Drug: Capecitabine;   Drug: Nab-Paclitaxel
Sponsor:   NewLink Genetics Corporation
Recruiting - verified July 2015

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Condition:   Dyslipidemia
Interventions:   Biological: Evolocumab (AMG 145);   Other: Placebo;   Drug: Effective statin therapy
Sponsor:   Amgen
Active, not recruiting - verified June 2015

SILVER-AMI: Outcomes in Older Persons With Heart Attacks

Condition:   Acute Myocardial Infarction
Intervention:  
Sponsors:   Sarwat Chaudhry;   National Heart, Lung, and Blood Institute (NHLBI)
Enrolling by invitation - verified July 2015

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition:   Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Correlations Between Arrhythmias and Air Pollution in Patients With Pacemaker and ICD

Condition:   Cardiac Arrhythmias
Intervention:  
Sponsor:   Effect Group, Italy
Completed - verified July 2015

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2015

Role of Stem Cells in Improving Implantation Rates in ICSI Patients

Condition:   Assess the Efficacy of Differentiated and Undifferentiated Stem Cell Therapy in Improving Endometrial Receptivity.
Interventions:   Biological: Differentiated stem cells to endometrium is deposited in the uterine cavity through an IUI catheter;   Biological: Undifferentiated MSC is deposited in the uterine cavity through an IUI catheter.
Sponsor:   Kasr El Aini Hospital
Recruiting - verified July 2012

A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified June 2015

Polypharmacy in the Heart Failure Patient: Are All Prescribed Drug Classes Required? Statin Withdrawal Study

Condition:   Heart Failure
Interventions:   Drug: Withdrawal of statin therapy;   Drug: Statin therapy
Sponsor:   The Alfred
Completed - verified June 2015

Aspirin Withdrawal in Non-ischaemic Cardiomyopathy Study

Condition:   Heart Failure
Interventions:   Drug: Aspirin;   Other: withdrawal of aspirin
Sponsor:   The Alfred
Completed - verified June 2015

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2015

Intracoronary Infusion of Bone Marrow Mononuclear Cells in Patients With Previous Myocardial Infarction.

Condition:   Chronic Myocardial Ischemia
Intervention:   Other: Bone marrow mononuclear cells
Sponsors:   Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud;   Iniciativa Andaluza en Terapias Avanzadas 
Completed - verified November 2014

A Study of RoActemra/Actemra (Tocilizumab) in Comparison to Etanercept in Patients With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

Condition:   Cardiovascular Disease, Rheumatoid Arthritis
Interventions:   Drug: etanercept;   Drug: tocilizumab [RoActemra/Actemra]
Sponsor:   Hoffmann-La Roche
Active, not recruiting - verified July 2015

TomVasc - Vascular Effects of Tomato Extract

Conditions:   Ischemic Heart Disease;   Transient Ischemic Attack;   Stroke;   Peripheral Vascular Disease
Interventions:   Dietary Supplement: Ateronon;   Dietary Supplement: Placebo
Sponsors:   Cambridge University Hospitals NHS Foundation Trust;   Cambridge Theranostics Ltd
Completed - verified July 2012

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage

Conditions:   Brain Ischemia;   Intracranial Hemorrhages
Interventions:   Drug: Cilostazol;   Drug: Probucol;   Drug: Aspirin;   Drug: placebo of cilostazol;   Drug: placebo of aspirin;   Device: ankle-brachial index (ABI);   Device: intima-medial thickness (IMT);   Device: new asymptomatic brain hemorrhage;   Device: new ischemic lesions on follow-up FLAIR images
Sponsors:   Asan Medical Center;   Korea Otsuka Pharmaceutical Co.,Ltd.
Active, not recruiting - verified June 2015

BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV;   Drug: D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV;   Drug: Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet
Sponsor:   Bayer
Completed - verified June 2015

Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC

Conditions:   MonoMAC;   Myelodysplastic Syndrome;   Immunodeficiency
Interventions:   Procedure: Reduced-Intensity Hematopoietic Stem Cell;   Drug: Fludarabine;   Procedure: Total Body Irradiation (TBI);   Drug: Filgrastim;   Drug: Sirolimus;   Drug: Tacrolimus;   Drug: Ursodiol
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified July 2014

A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.

Condition:   Anemia
Interventions:   Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta);   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
Sponsor:   Hoffmann-La Roche
Recruiting - verified July 2015

VerifyNow French Registry

Conditions:   Stent Thrombosis;   Clopidogrel;   Aspirin;   Bleeding;   Angioplasty
Intervention:  
Sponsors:   Association Pour le Développement des Soins Cardiologiques de la ville de Chartres;   Medtronic;   Boston Scientific Corporation;   Cordis Corporation;   Abbott
Completed - verified June 2015

Vytorin on Carotid Intima-media Thickness and Overall Rigidity

Condition:   Cardiovascular Diseases
Interventions:   Drug: ezetimibe (+) simvastatin;   Drug: simvastatin;   Drug: pravastatin
Sponsors:   Hospital Universitario 12 de Octubre;   Merck Sharp & Dohme Corp.
Completed - verified August 2008

An Observational Study of TNKase in Patients Enrolled in the National Registry of Myocardial Infarction 4 and 5 (POST)

Condition:   Acute Myocardial Infarction
Intervention:  
Sponsor:   Genentech, Inc.
Completed - verified April 2008

A Clinical Trial of IntensiVE Dialysis

Conditions:   Renal Replacement Therapy;   Renal Dialysis;   End Stage Kidney Disease;   End Stage Renal Disease;   Uremia
Intervention:   Procedure: haemodialysis
Sponsors:   The George Institute;   National Health and Medical Research Council, Australia;   Baxter Healthcare Corporation
Completed - verified June 2013

Promoting Healthy Weight With 'Stability Skills First'

Condition:   Obesity
Intervention:   Behavioral: Behavioral weight-loss/lifestyle interventions
Sponsors:   Stanford University;   National Cancer Institute (NCI)
Completed - verified June 2015

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Conditions:   Hematologic Neoplasms;   Neural Tube Defects;   Myeloproliferative Disorders
Interventions:   Drug: Rituximab;   Drug: Fludarabine;   Drug: Cyclosporine;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Biological: T-Rapa cell DLI;   Procedure: T cell DLI;   Drug: Prednisone;   Procedure: Allogeneic HSCT;   Drug: Filgrastim
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified September 2014

The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction

Conditions:   Coronary Disease;   Ventricular Dysfunction, Left
Interventions:   Drug: Ivabradine;   Drug: Placebo
Sponsor:   Institut de Recherches Internationales Servier
Completed - verified June 2015

Does Prophylactic Coronary Artery Revascularization for High Risk Patients Reduce Long-term Risk of Mortality

Condition:   Cardiovascular Disease
Interventions:   Procedure: Vascular surgery with best medical treatment;   Procedure: Coronary artery bypass grafting (CABG);   Procedure: Percutaneous transluminal coronary angioplasty (PTCA)
Sponsor:   Department of Veterans Affairs
Completed - verified June 2015

Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

Conditions:   Graft vs Host Disease;   Healthy;   Lymphopenia
Intervention:   Drug: G-CSF
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2015

Get CardioSmart

You're Invited